Simulations Plus (NASDAQ:SLP) Updates FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $1.07 to $1.20 for the period, compared to the consensus EPS estimate of $0.63. The company issued revenue guidance of $90 million to $93 million, compared to the consensus revenue estimate of $91.76 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. JMP Securities initiated coverage on Simulations Plus in a report on Tuesday, July 16th. They set a “market perform” rating for the company. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Thursday, September 12th. Craig Hallum restated a “buy” rating and issued a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. Finally, KeyCorp assumed coverage on shares of Simulations Plus in a research report on Monday, July 29th. They set an “overweight” rating and a $47.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Simulations Plus Trading Down 0.8 %

Shares of SLP traded down $0.27 during midday trading on Wednesday, reaching $33.98. 399,370 shares of the stock were exchanged, compared to its average volume of 126,490. The company has a market capitalization of $679.94 million, a P/E ratio of 71.35 and a beta of 0.69. Simulations Plus has a 52 week low of $29.37 and a 52 week high of $51.22. The company’s 50 day moving average is $33.35 and its two-hundred day moving average is $40.87.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total value of $625,200.00. Following the transaction, the director now owns 3,481,592 shares of the company’s stock, valued at $108,834,565.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 60,750 shares of company stock worth $2,145,055 over the last 90 days. Company insiders own 20.90% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.